Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Centessa Pharmaceuticals (CNTA) Net Income (2022 - 2025)

Centessa Pharmaceuticals (CNTA) has disclosed Net Income for 4 consecutive years, with -$66.2 million as the latest value for Q4 2025.

  • Quarterly Net Income rose 40.57% to -$66.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$197.5 million through Dec 2025, up 16.21% year-over-year, with the annual reading at -$197.5 million for FY2025, 16.21% up from the prior year.
  • Net Income for Q4 2025 was -$66.2 million at Centessa Pharmaceuticals, down from -$54.9 million in the prior quarter.
  • The five-year high for Net Income was -$24.9 million in Q2 2023, with the low at -$111.3 million in Q4 2024.
  • Average Net Income over 4 years is -$50.0 million, with a median of -$47.1 million recorded in 2024.
  • The sharpest move saw Net Income surged 61.51% in 2023, then plummeted 202.22% in 2024.
  • Over 4 years, Net Income stood at -$43.2 million in 2022, then rose by 14.68% to -$36.8 million in 2023, then tumbled by 202.22% to -$111.3 million in 2024, then skyrocketed by 40.57% to -$66.2 million in 2025.
  • According to Business Quant data, Net Income over the past three periods came in at -$66.2 million, -$54.9 million, and -$50.3 million for Q4 2025, Q3 2025, and Q2 2025 respectively.